Based on the Arrowhead Pharmaceuticals Inc stock forecast from 7 analysts, the average analyst target price for Arrowhead Pharmaceuticals Inc is USD 44.27 over the next 12 months. Arrowhead Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Arrowhead Pharmaceuticals Inc is Bearish, which is based on 1 positive signals and 8 negative signals. At the last closing, Arrowhead Pharmaceuticals Inc’s stock price was USD 13.34. Arrowhead Pharmaceuticals Inc’s stock price has changed by +18.68% over the past week, -13.94% over the past month and -42.72% over the last year.
No recent analyst target price found for Arrowhead Pharmaceuticals Inc
No recent average analyst rating found for Arrowhead Pharmaceuticals Inc
Company Overview Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicronemia syndrome; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; and Fazirsiran that is in Phase 3 clinical trial for the treatment of liver disease associated with alpha-1 antitrypsin deficiency. It also develops Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; GSK-4532990 to treat metabolic-dysfunction associated steatohepatitis (MASH); and Daplusiran/Tomligisiran which is in Phase 2 clinical trial for the treatment of Chronic Hepatitis B. In addition, the company is developing ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with MASH; ARO-INHBE to reduce the hepatic expression of the INHBE gene and its secreted gene product; ARO-RAGE to treat inflammatory lung disease; ARO-MUC5AC to treat muco-obstructive pulmonary diseases; and ARO-MMP7 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1/2a clinical trials. Further, it develops ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-DM1 to treat patient with Type 1 Myotonic Dystrophy; ARO-C3 to treat complement-mediated renal disease; ARO-CFB for the treatment of complement-mediated kidney disease that is in Phase 1/2a clinical trial; and ARO-ATXN2 for the treatment of Spinocerebellar Ataxia Type 2 that is in Phase 1 clinical trial. Arrowhead Pharmaceuticals, Inc. has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Horizon Therapeutics Ireland DAC; Takeda Pharmaceutical Company Limited; and with Amgen Inc. The company was founded in 2003 and is headquartered in Pasadena, California. Read Less
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's product pipeline includes Plozasiran, which has completed Phase 3 clinical trial to treat hypertriglyceridemia, dyslipidemia, and familial chylomicrone...Read More
Frequently Asked Questions About Arrowhead Pharmaceuticals Inc (ARWR) Stock
Based on ratings from 7 analysts Arrowhead Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on ARWR's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for ARWR is USD 44.27 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 21.
ARWR stock's Price/Earning ratio is 478.56.
Our analysis grades ARWR stock's Price / Earning ratio at F. This means that ARWR stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARWR may be a overvalued for its sector.
The last closing price of ARWR's stock was USD 13.34.
The most recent market capitalization for ARWR is USD 1.47B.
Based on targets from 7 analysts, the average taret price for ARWR is projected at USD 44.27 over the next 12 months.
This means that ARWR's stock price may go up by +231.88% over the next 12 months.
We can't find any ETFs which contains Arrowhead Pharmaceuticals Inc's stock.
As per our most recent records Arrowhead Pharmaceuticals Inc has 609 Employees.
Arrowhead Pharmaceuticals Inc's registered address is 177 East Colorado Boulevard, Pasadena, CA, United States, 91105.
You can get more information about it from Arrowhead Pharmaceuticals Inc's website at https://arrowheadpharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Frequently Asked Questions About Arrowhead Pharmaceuticals Inc (ARWR) Stock
Based on ratings from 7 analysts Arrowhead Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 9 buy, sell and 3 hold ratings.
Unfortunately we do not have enough data on ARWR's stock to indicate if its a good dividend stock.
Based on targets from 7 analysts, the average taret price for ARWR is USD 44.27 over the next 12 months. The maximum analyst target price is USD 60 while the minimum anlayst target price is USD 21.
ARWR stock's Price/Earning ratio is 478.56.
Our analysis grades ARWR stock's Price / Earning ratio at F. This means that ARWR stock's Price/Earning ratio is above 98% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this ARWR may be a overvalued for its sector.
The last closing price of ARWR's stock was USD 13.34.
The most recent market capitalization for ARWR is USD 1.47B.
Based on targets from 7 analysts, the average taret price for ARWR is projected at USD 44.27 over the next 12 months.
This means that ARWR's stock price may go up by +231.88% over the next 12 months.
We can't find any ETFs which contains Arrowhead Pharmaceuticals Inc's stock.
As per our most recent records Arrowhead Pharmaceuticals Inc has 609 Employees.
Arrowhead Pharmaceuticals Inc's registered address is 177 East Colorado Boulevard, Pasadena, CA, United States, 91105.
You can get more information about it from Arrowhead Pharmaceuticals Inc's website at https://arrowheadpharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for ARWR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
